{
    "nctId": "NCT02718144",
    "briefTitle": "Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer",
    "officialTitle": "A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "The number of patients with a dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with ER-positive and HER2-negative locally advanced and/or metastatic breast cancer, who progressed on standard therapies or for whom standard therapies are intolerant;\n* Patients should have experienced a natural or surgical menopause at least 5 years ago;\n* Failure of anti-estrogen treatment with tamoxifen and aromatase inhibitor(s) due to the development of resistance or unacceptable side effects with this treatment;\n* No undiagnosed vaginal bleeding;\n* No treatment with fulvestrant within 6 months of start of treatment;\n* Life expectancy at least 6 months;\n* Tumour assessment (CT scan) before the start of the E4 treatment;\n* Body mass index (BMI) between (\u2265) 18 and (\u2264) 35 kg/m2;\n* Able to swallow an oral medication;\n* Acceptable values of hematological parameters, liver and kidney function and calcium levels;\n* Acceptable values of hemostasis parameters (as of second cohort);\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2 (as of second cohort);\n* Reasonable physical and mental health as judged by the investigator and determined by physical examination, clinical laboratory assessments and vital signs;\n* Willing to give informed consent in writing.\n\nExclusion Criteria:\n\n* Uncontrolled nausea, vomiting, or diarrhea;\n* History of venous or arterial thromboembolic disease or a known defect in the blood coagulation system;\n* History of severe cardiac events or life threatening cardiac dysrhythmia (as of second cohort);\n* Patients who have unstable angina or clinical congestive heart failure (as of second cohort);\n* Uncontrolled hypertension, i.e. systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg in the last 6 months with or without medication;\n* Diabetes mellitus with poor glycaemic control in the last 6 months (HbA1c above 7.5%);\n* Any other serious disease including systemic lupus erythematosus and untreated cholelithiasis;\n* Smoking \\>10 cigarettes/day;\n* Use of any other cancer therapy including radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, chemotherapy, or use of other investigational agents at the start of treatment.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}